Back to results
US 2011/0212139 A1Published application
High-density lipoprotein coated medical devices
AssigneeAdvanced Cardiovascular Systems, Inc.
InventorNi Ding
Life of this patent
Estimating the term…
Abstract
Method are disclosed for local and systemic administration HDL, recombinant HDL or HDLm for the prevention, treatment, or amelioration of a vascular disorder, disease or occlusion such as restenosis or vulnerable plaque.
Claims11
A method of treating a medical condition, comprising implanting in a human being an implantable medical device, wherein the implantable medical device comprises
- a coating comprising a hydrophobic polymer and a high-density lipoprotein mimic (HDLm) and a biobeneficial material,
- wherein the hydrophobic polymer is a polyester selected from the group consisting of poly(D, L-lactic acid) (PDLLA), poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(D, L-lactic acid-co-glycolic acid) (PDLLGA), poly(glycolic acid) (PGA), polyhydroxyalkanoates (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), polycaprolactone (PCL), and a combination thereof,
- wherein the implantable medical device comprises a stent suitable for use in a blood vessel, and
- wherein HDLm comprises a polypeptide moiety that mimics the structure or function of a domain of apoA-I, apoA-II, or AI/AII-HDL.
1 more element
A method of treating a vascular disorder of a patient, comprising implanting in the patient an implantable medical device, wherein the implantable medical device comprises
- a coating comprising a hydrophobic polymer and a high-density lipoprotein mimic (HDLm) and a biobeneficial material,
- wherein the hydrophobic polymer is a polyester selected from the group consisting of poly(D, L-lactic acid) (PDLLA), poly(L-lactic acid) (PLLA), poly(D-lactic acid) (PDLA), poly(D, L-lactic acid-co-glycolic acid) (PDLLGA), poly(glycolic acid) (PGA), polyhydroxyalkanoates (PHA), poly(3-hydroxybutyrate) (PHB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanoate), polycaprolactone (PCL), and a combination thereof,
- wherein the implantable medical device comprises a stent suitable for use in a blood vessel, and
- wherein HDLm comprises a polypeptide moiety that mimics the structure or function of a domain of apoA-I, apoA-II, or AI/AII-HDL.
1 more element
Dependencies are inferred from the claim text.